Clinical Trial to Evaluate Safety and Efficacy of Thinqure20 (A Herbal Composition) in the Treatment and Prophylaxis of Novel Coronavirus and
Testing its In vitro- Potential against MS2 Bacteriophagae, Corona Virus, Influenza Virus and Mucor racemosus

Milind      Gharpure; Hrishikesh      Rangnekar; Pranjali   P   Dhawal; Nikhil      Varma

doi:10.2174/0126667975283266240304095915

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

Background and Objective: Thinqure20 is a polyherbal, reverse-pharmacology-based formulation that contains Piper longum, Piper nigrum, Zingiber officinale, and rock salt as active ingredients. It is designed to work as an effective antiviral agent and also as a preventive measure against SARS-CoV-2. Clinical and non-clinical studies have established significant safety efficacy and tolerability of Thinqure20 formulation in the treatment of COVID-19 infection.

Methods: In vivo human study was conducted on COVID-19 patients for 5 days. A total of 30 Covid-19 patients (n = 30) were enrolled. In vitro, cell line studies were also carried out to evaluate the potential effectiveness of Thinqure20 polyherbal formulation as an antiviral, antifungal, and Angiotensin- Converting Enzyme 2 (ACE2) inhibition.

Results: Human studies have demonstrated a mean percentage of reduction in viral load from baseline to end of the study visit which was found to be 75.4%. The minimum and maximum reduction in viral load was found to be 59.3% and 100%, respectively. Viral load testing was carried out by Reverse Transcriptase-quantitative Polymerase Chain Reaction (RT-qPCR) test. In vitro studies of Thinqure, 20 extracts showed potential antiviral activity against MS2 bacteriophage, influenza, and human coronavirus, antifungal activity against Mucor racemosus, and significant ACE2 receptor inhibition.

Conclusion: Thinqure20, a polyherbal formulation, is a potentially effective antiviral agent against non-enveloped viruses (MS2 bacteriophage), enveloped viruses (influenza and human coronavirus), and antifungal agent against mucor strains. It is also proven to be effective in the treatment of COVID-19 and can be attributed to an early recovery by the reduction in viral load.

Clinical Trail Registration Number: CTRI/2021/03/032471.

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0126667975283266240304095915	Print ISSN 2666-7967
Publisher Name Bentham Science Publisher	Online ISSN 2666-7975

Coronaviruses

Clinical Trial to Evaluate Safety and Efficacy of Thinqure20 (A Herbal Composition) in the Treatment and Prophylaxis of Novel Coronavirus and Testing its In vitro- Potential against MS2 Bacteriophagae, Corona Virus, Influenza Virus and Mucor racemosus

Abstract Play Pause

Related Journals

Related Books

Abstract